An expert panel delivers news to inform therapy and monitoring decisions, including a look at how the I-SPY 2 trial is accelerating evaluation of promising agents in high-risk breast cancer (as well as cutting down on unlikely-to-help treatments); opportunities to reduce late recurrence in patients with HR-positive tumors; better ways to address immunotherapy's toxic effects in survivors, part of the mission of UCSF's new CITE (Cancer Immunotherapy Toxicity Evaluation) Program; and immediate steps to take when cancer survivors present with fatigue, thirst or other hormonal symptoms.
Published
May 5, 2023
Created by
Related Presenters
Director of the Carol Franc Buck Breast Care Center
Laura Esserman is a surgeon, breast cancer oncology specialist, and director of the Carol Franc Buck Breast Care Center at UCSF.
Breast oncologist
Dr. Jo Chien specializes in caring for patients with breast cancer. She serves as medical director of breast medical oncology at UCSF.
Oncologist and melanoma specialist
Dr. Katy K. Tsai is a medical oncologist who specializes in treating melanoma and other skin cancers.
Endocrinologist
Dr. Zoe Quandt is an endocrinologist caring for patients who develop hormonal side effects from their cancer treatment, especially from immunotherapy (treatments that stimulate the immune system). She works with patients so they can continue critical can
